Moderna says its COVID-19 shot generates 'robust' response in children 6 to 11

Shares of Moderna Inc. gained 0.9% in premarket trading on Monday after the company shared interim data from a Phase 2/3 clinical study evaluating its COVID-19 vaccine in children between the ages of 6 and 11 years old. The trial, which has 4,753 participants between the ages of 6 and 11, evaluated the immune response one month after the second dose.